Desensitization in ABO-Incompatible Kidney Transplantation With Low ABO Iso-Agglutinin Titers

Transplant Proc. 2015 Oct;47(8):2340-3. doi: 10.1016/j.transproceed.2015.08.021.

Abstract

Background: In ABO-incompatible (ABOi) kidney transplantation (KT) with low iso-agglutinin (IG) titers (IGT), standard pre-conditioning treatment might be excessive. To try to answer this question, we evaluated the pre-conditioning requirements of a group of ABOi KT with low ABO IGT in our center. Our main objective was to assess desensitization requirements for ABOi KT with low IGT (<16) at Hospital Clinic of Barcelona from 2006 to 2014.

Methods: A retrospective study of desensitization (rituximab and plasma exchange [PE]) requirements for ABOi KT with IGT <16 was conducted.

Results: One and 5 years after KT, patient survival was 100%. Renal graft survival was 90% at 1 and 5 years after KT. Mean PE performed before KT was 1.7 (standard deviation [SD], 1.703); 50% of the patients did not receive PE after transplantation, 30% received 2 sessions of PE, and 20% received only 1. The average is 0.8 (SD, 0.91).Follow-up IG determinations remained with low titers (≤8/8). No rebounds of titers were observed during the first 4 to 6 months after transplantation.

Conclusions: Recipients with IGT ≤8 required none or only 1 PE session to reach acceptable titers (titers ≤4) to perform ABOi KT safely. This information is useful to assess the possibility of a minimized desensitization protocol in ABOi KT donors with low titers of IG to reduce adverse effects, reduce cost, and simplify pre-transplant logistics.

MeSH terms

  • ABO Blood-Group System*
  • Adult
  • Aged
  • Agglutinins / blood*
  • Blood Group Incompatibility / blood*
  • Blood Group Incompatibility / immunology
  • Desensitization, Immunologic*
  • Female
  • Graft Survival / immunology
  • Humans
  • Immunologic Factors / therapeutic use
  • Kidney Failure, Chronic / blood
  • Kidney Failure, Chronic / surgery*
  • Kidney Transplantation*
  • Male
  • Middle Aged
  • Plasma Exchange
  • Retrospective Studies
  • Rituximab / therapeutic use
  • Young Adult

Substances

  • ABO Blood-Group System
  • Agglutinins
  • Immunologic Factors
  • Rituximab